Indication: 1. It has a good effect on positive symptoms such as excitement, agitation, hallucination, delusion, thinking disorder and behavioral disorder. It is used for schizophrenia, mania or other psychotic disorders. 2. It can stop vomiting, vomiting or intractable hiccups caused by various reasons.

Indication: It is used for acute and chronic schizophrenia, mania, Tourette syndrome. It is effective in controlling excitement, agitation, hostility and aggressive behavior. Because this product has fewer adverse reactions to the cardiovascular system, it can also be used for organic brain disorders and senile mental disorders.

Indication: Used for pre-anesthetic administration, tremor paralysis, motion sickness, manic psychosis, gastrointestinal, gallbladder and kidney smooth muscle spasm, excessive gastric acid secretion, septic shock, and organophosphorus pesticide poisoning.

Indication: Sertraline is used to treat symptoms related to depression, including depression with anxiety, with or without a history of mania. After satisfactory treatment, continued use of sertraline can effectively prevent the recurrence and recurrence of depression. Sertraline is also used to treat obsessive-compulsive disorder. After the initial treatment responds, sertraline maintains its effectiveness, safety and tolerability in the treatment of obsessive-compulsive disorder for two years.

Indication: It is used to treat various types of epilepsy. It can also be used to treat manic episodes of bipolar disorder.

Indication: Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1. 1 Adults: Efficacy was established in three 6-week trials and one maintenance trial. 1 Adolescents (ages 12-17): Efficacy was established in one 6-week trial. 1 Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. 2 Efficacy was established in two 6-week trials in adult patients. 2 Paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see Clinical Studies (14. 1) The efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. Paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see Clinical Studies (14. 2) The efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults.

Indication: Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1. 1 Adults: Efficacy was established in three 6-week trials and one maintenance trial. 1 Adolescents (ages 12-17): Efficacy was established in one 6-week trial. 1 Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. 2 Efficacy was established in two 6-week trials in adult patients. 2 Paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see Clinical Studies (14. 1) The efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. Paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see Clinical Studies (14. 2) The efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults.

Indication: Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1. 1 Adults: Efficacy was established in three 6-week trials and one maintenance trial. 1 Adolescents (ages 12 to 17): Efficacy was established in one 6-week trial. 1 Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. 2 Efficacy was established in two 6-week trials in adult patients. 2 Paliperidone extended-release tablets are indicated for the treatment of schizophrenia [ see CLINICAL STUDIES ( 14. 1 The efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. Paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see CLINICAL STUDIES ( 14. 2 The efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults.

Indication: Paliperidone is an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1. 2 Paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see Clinical Studies (14. 1 Paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see Clinical Studies (14.